Balchem Co. (NASDAQ:BCPC) Shares Sold by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG cut its stake in shares of Balchem Co. (NASDAQ:BCPC) by 21.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,777 shares of the basic materials company’s stock after selling 3,008 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Balchem were worth $1,757,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in BCPC. Westside Investment Management Inc. purchased a new stake in shares of Balchem in the 3rd quarter valued at approximately $27,000. R Squared Ltd acquired a new position in shares of Balchem during the fourth quarter worth $29,000. Wilmington Savings Fund Society FSB purchased a new position in Balchem in the third quarter valued at $35,000. Venturi Wealth Management LLC purchased a new stake in Balchem during the 4th quarter worth about $95,000. Finally, Smartleaf Asset Management LLC boosted its position in shares of Balchem by 230.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 645 shares of the basic materials company’s stock worth $106,000 after acquiring an additional 450 shares in the last quarter. Institutional investors and hedge funds own 87.91% of the company’s stock.

Balchem Stock Up 0.1 %

Balchem stock opened at $167.35 on Thursday. The stock has a 50-day simple moving average of $165.56 and a 200-day simple moving average of $169.22. The company has a market capitalization of $5.44 billion, a P/E ratio of 42.58, a PEG ratio of 4.41 and a beta of 0.63. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.16 and a current ratio of 1.99. Balchem Co. has a fifty-two week low of $137.69 and a fifty-two week high of $186.03.

Balchem (NASDAQ:BCPC) last issued its quarterly earnings data on Friday, February 21st. The basic materials company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.11 by ($0.08). The firm had revenue of $240.00 million during the quarter, compared to analysts’ expectations of $239.96 million. Balchem had a net margin of 13.47% and a return on equity of 11.37%. Equities research analysts expect that Balchem Co. will post 4.64 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on BCPC shares. Sidoti raised Balchem to a “hold” rating in a research report on Tuesday, February 25th. StockNews.com downgraded shares of Balchem from a “buy” rating to a “hold” rating in a research report on Tuesday, February 25th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $190.00 target price on shares of Balchem in a research report on Monday, February 24th.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.